12 , e007071 (2019)
In a statement published alongside the results, Amgen said: Weight loss had not plateaued by 52 weeks, indicating the potential for further weight reduction. It added that improvements were recorded across other cardiometabolic measures, including waist circumference, blood pressure, high-sensitivity C-reactive protein (hs-CRP) and select lipid parameters
Any change in medication must be supported by your doctors supervision, though
Investors should track the net sales to gross sales ratio over the next four to six quarters as payer mix evolves: if net-to-gross deteriorates faster than patient volume grows, it signals that payer-mandated step therapy requirements are limiting the addressable population more than the companys guidance implies
However, our bodies take a little while to catch up
Patients taking ACE inhibitors or ARBs alongside spironolactone carry higher hyperkalemia risk when GLP-1 therapy is added